Expression of Vascular Endothelial Growth Factor in Uveal Melanoma
A prerequisite for the growth, progression and metastasis of malignant tumors of any localization is the development of its own vascular network. Newly formed vessels not only nourish the primary tumor, but also create conditions for the spread of tumor cells through the circulatory system and the f...
Saved in:
Published in | Oftalmologii͡a Vol. 18; no. 4; pp. 914 - 921 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English Russian |
Published |
Ophthalmology Publishing Group
29.12.2021
|
Subjects | |
Online Access | Get full text |
ISSN | 1816-5095 2500-0845 |
DOI | 10.18008/1816-5095-2021-4-914-921 |
Cover
Abstract | A prerequisite for the growth, progression and metastasis of malignant tumors of any localization is the development of its own vascular network. Newly formed vessels not only nourish the primary tumor, but also create conditions for the spread of tumor cells through the circulatory system and the formation of distant metastases. Angiogenesis is able to launch a small population of tumors from 100–300 cells that have accumulated genetic aberrations and have begun to express proangigenic molecules. The phenomenon is known as “transformation of tumor cells into angiogenic phenotype”. A tumor with angiogenic phenotype carries a high potential for proliferation and malignization. This pattern has been found in many types of cancer, but studied less in uveal melanoma. Meanwhile, in this aspect, uveal melanoma, metastasizing exclusively in a hematogenic way, with its selective, organotropic nature of metastasis, becomes an attractive model for the study of the molecular “scenario” of tumor angiogenesis studies allow us to say that, UM is subject to the general patterns of the development of malignant tumors. As with many types of tumors, VEGF is an obligate condition for the development and progression of UM. The VEGF molecule’s producers in UM are two cell populations: endothelial vascular cells and tumor cells. VEGF’s expression in UM is cyclical. The cycle is re-initiated, apparently, by increasing cell density in tumor proliferate and the development of hypoxia zones. We found no correlation between the intensity of pigmentation, necrosis, hemorrhage, germination in the corner of the front chamber, ophthalmohypertension on the one hand, and expression of VEGF in UM cells on the other. At the same time, a direct link between the expression of VEGF in tumor cells and EC vessels on the one hand and the thickness, base diameter, as well as the localization of UM, on the other hand, has been revealed. Additionally, VEGF expression in tumor cells was closely correlated with the histological structure of UM, and VEGF expression in EC correlated with the stage of the disease. Thus, the authors showed that UM, like other malignant solid tumors, is prone to transformation into angiogenic phenotype and expression of VEGF. |
---|---|
AbstractList | A prerequisite for the growth, progression and metastasis of malignant tumors of any localization is the development of its own vascular network. Newly formed vessels not only nourish the primary tumor, but also create conditions for the spread of tumor cells through the circulatory system and the formation of distant metastases. Angiogenesis is able to launch a small population of tumors from 100–300 cells that have accumulated genetic aberrations and have begun to express proangigenic molecules. The phenomenon is known as “transformation of tumor cells into angiogenic phenotype”. A tumor with angiogenic phenotype carries a high potential for proliferation and malignization. This pattern has been found in many types of cancer, but studied less in uveal melanoma. Meanwhile, in this aspect, uveal melanoma, metastasizing exclusively in a hematogenic way, with its selective, organotropic nature of metastasis, becomes an attractive model for the study of the molecular “scenario” of tumor angiogenesis studies allow us to say that, UM is subject to the general patterns of the development of malignant tumors. As with many types of tumors, VEGF is an obligate condition for the development and progression of UM. The VEGF molecule’s producers in UM are two cell populations: endothelial vascular cells and tumor cells. VEGF’s expression in UM is cyclical. The cycle is re-initiated, apparently, by increasing cell density in tumor proliferate and the development of hypoxia zones. We found no correlation between the intensity of pigmentation, necrosis, hemorrhage, germination in the corner of the front chamber, ophthalmohypertension on the one hand, and expression of VEGF in UM cells on the other. At the same time, a direct link between the expression of VEGF in tumor cells and EC vessels on the one hand and the thickness, base diameter, as well as the localization of UM, on the other hand, has been revealed. Additionally, VEGF expression in tumor cells was closely correlated with the histological structure of UM, and VEGF expression in EC correlated with the stage of the disease. Thus, the authors showed that UM, like other malignant solid tumors, is prone to transformation into angiogenic phenotype and expression of VEGF. |
Author | Stepanova, E. V. Ovanesyan, V. E. Anurova, O. A. Likhvantseva, V. G. Astakhova, S. E. Vereshchagina, M. V. |
Author_xml | – sequence: 1 givenname: V. G. orcidid: 0000-0002-3175-9592 surname: Likhvantseva fullname: Likhvantseva, V. G. organization: A.I. Burnazyan Federal Biophysical Center of FMBA of Russia – sequence: 2 givenname: O. A. surname: Anurova fullname: Anurova, O. A. organization: National Medical Research Center for Obstetrics, Gynecology and Perinatology named after academician V.I. Kulakov – sequence: 3 givenname: S. E. surname: Astakhova fullname: Astakhova, S. E. organization: Academy of Postgraduate Education of the Federal Scientific and Clinical Cente for Specialized Medical Assistance and Medical Technologies of FMBA of Russia – sequence: 4 givenname: M. V. surname: Vereshchagina fullname: Vereshchagina, M. V. organization: Children’s City Polyclinic No. 15, Ambulatory аnd Polyclinic Center – sequence: 5 givenname: V. E. surname: Ovanesyan fullname: Ovanesyan, V. E. organization: Yegoryev Central District Hospital – sequence: 6 givenname: E. V. surname: Stepanova fullname: Stepanova, E. V. organization: Research Institute of Experimental Diagnostics and Therapy of Tumors of National Medical Research Center of Oncology named after N.N. Blokhin |
BookMark | eNqNkMtOwzAQRS0EEqX0H8IHBGYcO7FXCKpSKhWxoWytqWPTVCGunPD6exKKumDFYjTS1b1ncc7YcRMax9gFwiUqAHWFCvNUgpYpB46pSDX2x_GIjbgESEEJecxGh9opm7TtFgBQIiLPR-x29rmLrm2r0CTBJ8_U2reaYjJrytBtXF1Rncxj-Og2yR3ZLsSkapLVu-vjB1dTE17pnJ14qls3-f1jtrqbPU3v0-XjfDG9WaaW8wxTrVQJupQFl9IrKrkD7gnX3tFaePJcrAsnhHaqVNoKyDHPrcglCFWUQmA2Zos9twy0NbtYvVL8MoEq8xOE-GIodpWtnclc5qwHrZAKoWGtIFcyk0IXHAdkz9J7lo2hbaPzBx6C-XFrBmlmkGYGt0aY3q3p3fbb6z9bW3XU9Qa7SFX9D8I32TR_qQ |
CitedBy_id | crossref_primary_10_18008_1816_5095_2022_3_594_602 |
Cites_doi | 10.1136/bjophthalmol-2020-317949 10.1001/archopht.124.10.1428 10.1634/theoncologist.9-suppl_1-2 10.3109/02713683.2010.534573 10.1136/bjo.84.7.750 10.1167/iovs.09-4739 10.1097/00008390-200008000-00006 10.1002/9780471420194.tnmc26.pub3 10.1001/archopht.120.4.466 10.1038/eye.1997.57 10.1016/0046-8177(92)90299-I 10.1210/edrv.18.1.0287 10.1016/S0161-6420(93)31470-3 10.1136/bjo.86.4.448 10.1111/1523-1747.ep12470222 |
ContentType | Journal Article |
DBID | AAYXX CITATION DOA |
DOI | 10.18008/1816-5095-2021-4-914-921 |
DatabaseName | CrossRef DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2500-0845 |
EndPage | 921 |
ExternalDocumentID | oai_doaj_org_article_3e3ecf0981a7490b8068535497214650 10_18008_1816_5095_2021_4_914_921 |
GroupedDBID | 5VS AAYXX ALMA_UNASSIGNED_HOLDINGS CITATION GROUPED_DOAJ KQ8 |
ID | FETCH-LOGICAL-c2231-988d09d57255f8ad2e02fa1bfeab4faf24b7e449e8d89c406166c4650487d4413 |
IEDL.DBID | DOA |
ISSN | 1816-5095 |
IngestDate | Wed Aug 27 01:18:26 EDT 2025 Thu Apr 24 23:05:22 EDT 2025 Tue Jul 01 01:03:31 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English Russian |
License | https://www.ophthalmojournal.com/opht/about/editorialPolicies#openAccessPolicy |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c2231-988d09d57255f8ad2e02fa1bfeab4faf24b7e449e8d89c406166c4650487d4413 |
ORCID | 0000-0002-3175-9592 |
OpenAccessLink | https://doaj.org/article/3e3ecf0981a7490b8068535497214650 |
PageCount | 8 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_3e3ecf0981a7490b8068535497214650 crossref_primary_10_18008_1816_5095_2021_4_914_921 crossref_citationtrail_10_18008_1816_5095_2021_4_914_921 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-12-29 |
PublicationDateYYYYMMDD | 2021-12-29 |
PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-29 day: 29 |
PublicationDecade | 2020 |
PublicationTitle | Oftalmologii͡a |
PublicationYear | 2021 |
Publisher | Ophthalmology Publishing Group |
Publisher_xml | – name: Ophthalmology Publishing Group |
References | ref13 ref12 ref15 ref14 ref11 ref10 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref25 ref20 ref22 ref21 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
References_xml | – ident: ref1 – ident: ref3 – ident: ref16 doi: 10.1136/bjophthalmol-2020-317949 – ident: ref5 – ident: ref7 – ident: ref22 doi: 10.1001/archopht.124.10.1428 – ident: ref19 doi: 10.1634/theoncologist.9-suppl_1-2 – ident: ref24 – ident: ref25 doi: 10.3109/02713683.2010.534573 – ident: ref23 doi: 10.1136/bjo.84.7.750 – ident: ref20 doi: 10.1167/iovs.09-4739 – ident: ref17 doi: 10.1097/00008390-200008000-00006 – ident: ref13 – ident: ref15 doi: 10.1002/9780471420194.tnmc26.pub3 – ident: ref4 – ident: ref2 – ident: ref18 doi: 10.1001/archopht.120.4.466 – ident: ref11 doi: 10.1038/eye.1997.57 – ident: ref8 doi: 10.1016/0046-8177(92)90299-I – ident: ref6 doi: 10.1210/edrv.18.1.0287 – ident: ref9 doi: 10.1016/S0161-6420(93)31470-3 – ident: ref21 doi: 10.1136/bjo.86.4.448 – ident: ref12 – ident: ref10 doi: 10.1111/1523-1747.ep12470222 – ident: ref14 |
SSID | ssj0001511126 |
Score | 2.168364 |
Snippet | A prerequisite for the growth, progression and metastasis of malignant tumors of any localization is the development of its own vascular network. Newly formed... |
SourceID | doaj crossref |
SourceType | Open Website Enrichment Source Index Database |
StartPage | 914 |
SubjectTerms | angiogenesis immunohystochemical analysis markers of endothelial cells prognosis uveal melanoma |
Title | Expression of Vascular Endothelial Growth Factor in Uveal Melanoma |
URI | https://doaj.org/article/3e3ecf0981a7490b8068535497214650 |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NSwMxEA3SQ_EifmL9IoLX0E02u0mOVlqLUE9WegvJboJC3UppxZ_vzO5a6kkPHvYSmLA8XnbeYzMzhNxo56XygbMQo2Yy9RlzqXHMy6JQyqNIwNrhyWM-nsqHWTbbGvWFd8Ka9sANcP00pKGIidHcKWkSr5McMgy4GoUjqRu3nphky0w19cEca2PQbWmeM8iKWZdc4xcCBJLubxaBJAI8FBx5eAT_kZy2evjXyWa0T_ZalUhvm7c7IDvL9SHpTtr_4EdkMPxsL7BWdBHpc3udlA6rEiuq5kAqeg8Ge_VCR_VAHfpa0ekHiEI6CXNXLd7cMZmOhk93Y9ZOQ2AFpHDOjNZlYspMgQmI2pUiJCI67mMAuKOLQnoVpDRBl9oUmKfzvECEwJKUIHrSE9KpFlU4JVR4EA2RB6dEKr3zxvNoVAIbZKEsXN4j-hsGW7StwnFixdyiZUAELSJoEUGLCFppAUELCPaI2IS-N_0y_hI0QKw3Adjyul4AItiWCPY3Ipz9xybnZLdmBBdMmAvSWS3X4RJUx8pf1QT7Avrcycc |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Expression+of+Vascular+Endothelial+Growth+Factor+in+Uveal+Melanoma&rft.jtitle=Oftalmologii%CD%A1a&rft.au=V.+G.+Likhvantseva&rft.au=O.+A.+Anurova&rft.au=S.+E.+Astakhova&rft.au=M.+V.+Vereshchagina&rft.date=2021-12-29&rft.pub=Ophthalmology+Publishing+Group&rft.issn=1816-5095&rft.eissn=2500-0845&rft.volume=18&rft.issue=4&rft.spage=914&rft.epage=921&rft_id=info:doi/10.18008%2F1816-5095-2021-4-914-921&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_3e3ecf0981a7490b8068535497214650 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1816-5095&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1816-5095&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1816-5095&client=summon |